keyword
MENU ▼
Read by QxMD icon Read
search

Incretins

keyword
https://www.readbyqxmd.com/read/29028177/postmeal-increment-in-intact-glucagon-like-peptide-1-level-but-not-intact-glucose-dependent-insulinotropic-polypeptide-levels-is-inversely-associated-with-metabolic-syndrome-in-patients-with-type-2-diabetes
#1
Soyeon Yoo, Eun-Jin Yang, Sang Ah Lee, Gwanpyo Koh
PURPOSE: Metabolic syndrome increases the risk of cardiovascular disease. Recently glucagon-like peptide 1 (GLP-1) agonists proved to be effective in preventing cardiovascular disease (CVD) in patients with type 2 diabetes. We investigated the association of blood incretin levels with metabolic syndrome in patients with type 2 diabetes. MATERIALS AND METHODS: This is a cross-sectional study involving 334 people with type 2 diabetes. Intact GLP-1 (iGLP-1) and intact glucose-dependent insulinotropic polypeptide (iGIP) levels were measured in a fasted state and 30 min after ingestion of a standard mixed meal...
October 13, 2017: Endocrine Research
https://www.readbyqxmd.com/read/29021350/is-the-way-to-someone-s-heart-through-their-stomach-the-cardiorenal-paradox-of-incretin-based-hypoglycemic-drugs-in-heart-failure
#2
Milton Packer
No abstract text is available yet for this article.
October 2017: Circulation. Heart Failure
https://www.readbyqxmd.com/read/29017497/the-effects-of-vildagliptin-compared-with-metformin-on-vascular-endothelial-function-and-metabolic-parameters-a-randomized-controlled-trial-sapporo-athero-incretin-study-3
#3
Naoyuki Kitao, Hideaki Miyoshi, Tomoo Furumoto, Kota Ono, Hiroshi Nomoto, Aika Miya, Chiho Yamamoto, Atsushi Inoue, Kenichi Tsuchida, Naoki Manda, Yoshio Kurihara, Shin Aoki, Akinobu Nakamura, Tatsuya Atsumi
BACKGROUND: Dipeptidyl peptidase-4 (DPP-4) inhibitors may have protective effects in the early stage of atherosclerosis in patients with type 2 diabetes, although similar effects in advanced atherosclerosis were not shown in recent randomized placebo-controlled studies. Therefore, we investigated the efficacy of DPP-4 inhibitor on endothelial function and glycemic metabolism compared with high-dose metformin. METHODS: In this multicenter, open-labeled, prospective, randomized, parallel-group comparison study, patients with type 2 diabetes treated with low-dose metformin (500-750 mg/day) were enrolled and randomly assigned to a vildagliptin, a DPP-4 inhibitor, add-on group (Vilda) or a double dose of metformin group (high Met) for 12 weeks...
October 10, 2017: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/28982341/gastrin-a-potential-predictor-of-response-to-incretin-therapy-in-diabetes-type-2-patients
#4
Ines Bilic-Curcic, Maja Cigrovski Berkovic
BACKGROUND AND OBJECTIVES: Personalized management of diabetes has become an imperative since majority of monotherapy fails within 3 years of its use. Identifying responders from non-responders for a certain type of therapy would reduce a period of unsuccessful treatment and minimize health care costs. Incretin therapies, mainly glucagon-like peptide (GLP)-1 receptor agonists (GLP-1RA) are relatively new glucose-lowering agents which increase insulin and lower glucagon response as well as slow down glucose absorption by acting on gastric emptying...
October 3, 2017: Endocrine, Metabolic & Immune Disorders Drug Targets
https://www.readbyqxmd.com/read/28977602/dipeptidyl-peptidase-4-inhibition-with-saxagliptin-ameliorates-angiotensin-ii-induced-cardiac-diastolic-dysfunction-in-male-mice
#5
Scott M Brown, Cassandra E Smith, Alex I Meuth, Maloree Khan, Annayya R Aroor, Hannah M Cleeton, Gerald A Meininger, James R Sowers, Vincent G DeMarco, Bysani Chandrasekar, Ravi Nistala, Shawn B Bender
Activation of the renin-angiotensin-aldosterone system is common in hypertension and obesity and contributes to cardiac diastolic dysfunction, a condition for which no treatment currently exists. In light of recent reports that antihyperglycemia incretin enhancing dipeptidyl peptidase (DPP)-4 inhibitors exert cardioprotective effects, we examined the hypothesis that DPP-4 inhibition with saxagliptin (Saxa) attenuates angiotensin II (Ang II)-induced cardiac diastolic dysfunction. Male C57BL/6J mice were infused with either Ang II (500 ng/kg/min) or vehicle for 3 weeks receiving either Saxa (10 mg/kg/d) or placebo during the final 2 weeks...
October 1, 2017: Endocrinology
https://www.readbyqxmd.com/read/28958596/increased-levels-of-inflammatory-plasma-markers-and-obesity-risk-in-a-mouse-model-of-down-syndrome
#6
REVIEW
M Fructuoso, L Rachdi, E Philippe, R G Denis, C Magnan, H Le Stunff, N Janel, M Dierssen
Down syndrome (DS) is caused by the trisomy of human chromosome 21 and is the most common genetic cause of intellectual disability. In addition to the intellectual deficiencies and physical anomalies, DS individuals present a higher prevalence of obesity and subsequent metabolic disorders than healthy adults. There is increasing evidence from both clinical and experimental studies indicating the association of visceral obesity with a pro-inflammatory status and recent studies have reported that obese people with DS suffer from low-grade systemic inflammation...
September 25, 2017: Free Radical Biology & Medicine
https://www.readbyqxmd.com/read/28956360/effects-of-incretin-based-therapies-on-diabetic-microvascular-complications
#7
REVIEW
Yu Mi Kang, Chang Hee Jung
The morbidity and mortality associated with diabetic complications impose a huge socioeconomic burden worldwide. Therefore, the ultimate goal of managing diabetes mellitus (DM) is to lower the risk of macrovascular complications and highly morbid microvascular complications such as diabetic nephropathy (DN) and diabetic retinopathy (DR). Potential benefits of incretin-based therapies such as glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors on the diabetic macrovascular complications have been recently suggested, owing to their pleiotropic effects on multiple organ systems...
September 2017: Endocrinology and Metabolism
https://www.readbyqxmd.com/read/28950392/systemic-hypoxia-increases-the-expression-of-dpp4-in-preadipocytes-of-healthy-human-participants
#8
Helena H Chowdhury, Jelena Velebit, Igor B Mekjavic, Ola Eiken, Marko Kreft, Robert Zorec
Dipeptidyl peptidase 4 (DPP4) is a transmembrane glycoprotein involved in protein degradation. Due to its action on incretins, which increase insulin secretion, DPP4 is considered a therapeutic target for type 2 diabetes. Here we have studied the role of single and combined effects of hypoxia and inactivity on the expression of DPP4 in human adipose tissue of 12 adult normal-weight males. Fat biopsies were obtained at baseline and after each of three experimental campaigns. The results revealed that in isolated human preadipocytes the expression of DPP4 was significantly increased by exposure of participants to hypoxia...
September 26, 2017: Experimental and Clinical Endocrinology & Diabetes
https://www.readbyqxmd.com/read/28950045/non-st-elevation-myocardial-infarction-nstemi-outcome-in-type-2-diabetic-patients-with-non-obstructive-coronary-artery-stenosis-effects-of-incretin-treatment
#9
Raffaele Marfella, Celestino Sardu, Paolo Calabrò, Mario Siniscalchi, Fabio Minicucci, Giuseppe Signoriello, Maria Luisa Balestrieri, Ciro Mauro, Maria Rosaria Rizzo, Giuseppe Paolisso, Michelangela Barbieri
No proper data on prognosis and management of type-2 diabetic patients with non-obstructive coronary artery stenosis (NOCS)-Non-ST-Elevation Myocardial Infarction (NSTEMI) exist. We evaluated the 12-months prognosis of NOCS-diabetics (20-49% luminal stenosis) with first NSTEMI as compared with non-diabetics. Moreover, we investigated the 12-months prognosis in NSTEMI-NOCS diabetics, previously treated with incretin-based therapy, compared with a matched cohort of NSTEMI-NOCS never treated with such therapy...
September 26, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28948296/gip-3-30-nh2-is-an-efficacious-gip-receptor-antagonist-in-humans-a-randomised-double-blinded-placebo-controlled-crossover-study
#10
Lærke S Gasbjerg, Mikkel B Christensen, Bolette Hartmann, Amalie R Lanng, Alexander H Sparre-Ulrich, Maria B N Gabe, Flemming Dela, Tina Vilsbøll, Jens J Holst, Mette M Rosenkilde, Filip K Knop
AIMS/HYPOTHESIS: Glucose-dependent insulinotropic polypeptide (GIP) is an incretin hormone secreted postprandially from enteroendocrine K cells, but despite therapeutically interesting effects, GIP physiology in humans remains incompletely understood. Progress in this field could be facilitated by a suitable GIP receptor antagonist. For the first time in humans, we investigated the antagonistic properties of the naturally occurring GIP(3-30)NH2 in in vivo and in in vitro receptor studies...
September 25, 2017: Diabetologia
https://www.readbyqxmd.com/read/28943448/molecular-integration-of-incretin-and-glucocorticoid-action-reverses-immunometabolic-dysfunction-and-obesity
#11
Carmelo Quarta, Christoffer Clemmensen, Zhimeng Zhu, Bin Yang, Sini S Joseph, Dominik Lutter, Chun-Xia Yi, Elisabeth Graf, Cristina García-Cáceres, Beata Legutko, Katrin Fischer, Robert Brommage, Philippe Zizzari, Bernardo S Franklin, Martin Krueger, Marco Koch, Sabine Vettorazzi, Pengyun Li, Susanna M Hofmann, Mostafa Bakhti, Aimée Bastidas-Ponce, Heiko Lickert, Tim M Strom, Valerie Gailus-Durner, Ingo Bechmann, Diego Perez-Tilve, Jan Tuckermann, Martin Hrabě de Angelis, Darleen Sandoval, Daniela Cota, Eicke Latz, Randy J Seeley, Timo D Müller, Richard D DiMarchi, Brian Finan, Matthias H Tschöp
Chronic inflammation has been proposed to contribute to the pathogenesis of diet-induced obesity. However, scarce therapeutic options are available to treat obesity and the associated immunometabolic complications. Glucocorticoids are routinely employed for the management of inflammatory diseases, but their pleiotropic nature leads to detrimental metabolic side effects. We developed a glucagon-like peptide-1 (GLP-1)-dexamethasone co-agonist in which GLP-1 selectively delivers dexamethasone to GLP-1 receptor-expressing cells...
October 3, 2017: Cell Metabolism
https://www.readbyqxmd.com/read/28942790/glucagon-like-peptide-1-receptor-agonists-a-class-update-for-treating-type-2-diabetes
#12
REVIEW
Julie A Lovshin
Current management options for treating type 2 diabetes are diverse. Many different classes of antidiabetes therapies are used in clinic, and several new candidates are in late-phase clinical trial. This therapeutic abundance is a windfall for patients because it facilitates individualized patient care. Evidence-based positioning of these agents is challenging, however, requiring comprehensive and balanced familiarity with each drug class. In this review, I provide a clinical update of glucagon-like peptide-1 receptor agonists (GLP-1RAs), a class of incretin-based, injectable antidiabetes therapies which improve fasting and postprandial blood glucose control through glucose-dependent pancreatic islet cell hormone secretion without significant risks for hypoglycemia...
October 2017: Canadian Journal of Diabetes
https://www.readbyqxmd.com/read/28942740/the-role-of-whey-protein-in-postprandial-glycaemic-control
#13
Emma J Stevenson, Dean M Allerton
Epidemiological studies demonstrate that poor glycaemic control is an independent risk factor for CVD. Postprandial glycaemia has been demonstrated as a better predictor of glycated Hb, the gold standard of glycaemic control, when compared with fasting blood glucose. There is a need for more refined strategies to tightly control postprandial glycaemia, particularly in those with type 2 diabetes, and nutritional strategies around meal consumption may be effective in enhancing subsequent glycaemic control. Whey protein administration around meal times has been demonstrated to reduce postprandial glycaemia, mediated through various mechanisms including an enhancement of insulin secretion...
September 25, 2017: Proceedings of the Nutrition Society
https://www.readbyqxmd.com/read/28939430/do-non-nutritive-sweeteners-influence-acute-glucose-homeostasis-in-humans-a-systematic-review
#14
REVIEW
Robin M Tucker, Sze-Yen Tan
The human body associates sensory cues with metabolic consequences. Exposure to sweet-tasting sugars - even in the absence of ingestion - triggers physiological responses that are associated with carbohydrate digestion, absorption and metabolism. These responses include the release of insulin and incretin hormones, which work to reduce blood glucose. For this reason, non-nutritive sweeteners (NNS) have been posited to trigger similar physiological responses and reduce postprandial blood glucose concentrations...
September 20, 2017: Physiology & Behavior
https://www.readbyqxmd.com/read/28938487/regulation-of-endogenous-male-rodent-glp-1-secretion-and-human-islet-insulin-secretion-by-antagonism-of-somatostatin-receptor-5
#15
Thomas B Farb, Marta Adeva, Thomas J Beauchamp, Over Cabrera, David A Coates, Tamika DeShea Meredith, Brian A Droz, Alexander Efanov, James V Ficorilli, Susan L Gackenheimer, Maria A Martinez-Grau, Victoriano Molero, Gema Ruano, Michael A Statnick, Todd M Suter, Samreen K Syed, Miguel A Toledo, Francis S Willard, Xin Zhou, Krister B Bokvist, David G Barrett
Incretin and insulin responses to nutrient loads are suppressed in persons with diabetes, resulting in decreased glycemic control. Whereas agents including sulfonylureas and Dipeptidyl peptidase-4 inhibitors (DPP4i) partially reverse these effects and provide therapeutic benefit, their modes of action limit efficacy. Because somatostatin (SST) has been shown to suppress both insulin and GLP-1 secretion through the Gi-coupled SST receptor 5 (SSTR5) isoform in vitro, antagonism of SSTR5 may improve glycemic control via intervention in both pathways...
September 11, 2017: Endocrinology
https://www.readbyqxmd.com/read/28938466/optogenetic-analysis-of-depolarization-dependent-glucagonlike-peptide-1-release
#16
Catalin Chimerel, Cristian Riccio, Keir Murison, Fiona M Gribble, Frank Reimann
Incretin hormones play an important role in the regulation of food intake and glucose homeostasis. Glucagonlike peptide-1 (GLP-1)-secreting cells have been demonstrated to be electrically excitable and to fire action potentials (APs) with increased frequency in response to nutrient exposure. However, nutrients can also be metabolized or activate G-protein-coupled receptors, thus potentially stimulating GLP-1 secretion independent of their effects on the plasma membrane potential. Here we used channelrhodopsins to manipulate the membrane potential of GLUTag cells, a well-established model of GLP-1-secreting enteroendocrine L cells...
October 1, 2017: Endocrinology
https://www.readbyqxmd.com/read/28924374/no-association-of-proton-pump-inhibitor-use-with-fasting-or-postload-glycaemia-in-patients-with-cardiovascular-disease-a-cross-sectional-retrospective-study
#17
Olga Kruszelnicka, Marcin Kuźma, Iwona Z Pena, Ian B Perera, Bernadeta Chyrchel, Ewa Wieczorek-Surdacka, Andrzej Surdacki
Background: Proton pump inhibitor (PPI) use was reportedly associated with an excess of adverse cardiovascular (CV) events, thus making their systemic effects relevant to public health. PPIs reduce gastric acid secretion, causing increased gastrin release. Gastrin stimulates β-cell neogenesis and enhances insulin release, exerting an incretin-like effect. Our aim was to assess, if PPI usage is associated with altered glycaemia in patients with CV disease. Methods: We retrospectively analyzed medical records of 102 subjects (80 with ischemic heart disease) who underwent a routine oral glucose tolerance test while hospitalized in a cardiology department...
2017: International Journal of Medical Sciences
https://www.readbyqxmd.com/read/28919867/sulfated-cholecystokinin-8-promotes-cd36-mediated-fatty-acid-uptake-into-primary-mouse-duodenal-enterocytes
#18
Claire Demenis, John McLaughlin, Craig P Smith
Cholecystokinin (CCK) is an archetypal incretin hormone secreted by intestinal enteroendocrine cells (EEC) in response to ingested nutrients. The aim of this study was to determine whether CCK modulates enterocyte fatty acid uptake by primary mouse duodenal cells. Exposure of primary mouse duodenal cells to 10 pM sulfated CCK-8 caused a two fold increase in dodecanoic acid fatty acid (FA) uptake. The selective CCK A receptor antagonist loxiglumide (100 μM) completely abolished the CCK-8 induced FA uptake. The CD36 fatty acid translocase-specific inhibitor sulfo-N-succinimidyl oleate (1 μM) also completely inhibited CCK-8 induced FA uptake, as did treatment with 200 μM phloretin...
2017: Frontiers in Physiology
https://www.readbyqxmd.com/read/28915418/purification-identification-and-molecular-mechanism-of-two-dipeptidyl-peptidase-iv-dpp-iv-inhibitory-peptides-from-antarctic-krill-euphausia-superba-protein-hydrolysate
#19
Wei Ji, Chaohua Zhang, Hongwu Ji
Dipeptidyl peptidase IV (DPP-IV) played an important role in blood glucose regulation. Inhibition of DPP-IV may improve glycemic control in diabetics by preventing the rapid breakdown of incretin hormones and prolonging their physiological action. In this study, Antarctic krill (Euphausia superba) protein was hydrolyzed using animal proteolytic enzymes. The hydrolysate was purified sequentially by ultrafiltration, gel filtration chromatography and reversed phase high-performance liquid chromatography (RP-HPLC)...
October 1, 2017: Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
https://www.readbyqxmd.com/read/28912925/incretin-kinetics-before-and-after-miglitol-in-japanese-patients-with-late-dumping-syndrome
#20
Mari Amagai, Hirohisa Tsuchiya, Yukari Chiba, Jun Suzuki, Jo Nagakura, Erina Shigematsu, Tadashi Yamakawa, Yasuo Terauchi
BACKGROUND: In patients with late dumping syndrome following gastrectomy, it has been reported that hypoglycemia occurs due to inhibition of glucagon secretion as a result of excessive insulin production facilitated by an increase in glucagon-like peptide-1 (GLP-1). METHODS: To determine the kinetics of incretins in Japanese patients with late dumping syndrome, an oral glucose tolerance test was carried out before and after miglitol administration, and the kinetics of insulin and incretins were analyzed...
October 2017: Journal of Clinical Medicine Research
keyword
keyword
4245
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"